证券代码：300294 证券简称：博雅生物 公告编号：2025-028 华润博雅生物制药集团股份有限公司 第八届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 华润博雅生物制药集团股份有限公司（以下简称公司）第八届董事会第十一 次会议于 2025 年 4 月 20 日以邮件及通讯方式通知，并于 2025 年 4 月 23 日在公 司会议室以现场加通讯表决的方式召开。会议应参加表决董事 9 人，实参加表决 董事 9 人。会议由董事长邱凯先生主持，公司全体监事出席会议，全体高级管理 人员列席会议。本次会议符合《中华人民共和国公司法》《中华人民共和国证券 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关规定。经充 分讨论，审议通过了以下议案。 具体内容详见同日在巨潮资讯网（网址：http://www.cninfo.com.cn）披露的 《2025 年第一季度报告》。 表决结果：9 票同意，0 票反对，0 票弃权。 2、审议通过《关于募 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 535,876,732.90, representing a 19.49% increase compared to CNY 448,452,537.26 in the same period last year[2] - The net profit attributable to shareholders decreased by 8.25% to CNY 139,484,155.03 from CNY 152,024,886.81 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 19.67% to CNY 102,261,123.10, down from CNY 127,306,750.41 in the previous year[3] - Operating profit for the current period was ¥162,436,766.94, a decrease of 7% from ¥174,748,795.31 in the previous period[19] - Net profit for the current period was ¥139,291,778.48, down 8.1% from ¥151,760,842.43 in the previous period[19] - The net profit attributable to the parent company was approximately ¥139.48 million, a decrease from ¥152.02 million in the previous period, representing a decline of about 8.5%[20] - The total comprehensive income attributable to the parent company was approximately ¥139.11 million, down from ¥152.02 million, reflecting a decrease of around 8.5%[20] - Basic and diluted earnings per share were both ¥0.28, compared to ¥0.30 in the previous period, indicating a decline of approximately 6.67%[20] Cash Flow - The net cash flow from operating activities was negative CNY 42,119,496.62, a decline of 134.00% compared to a positive CNY 123,871,710.13 in the same period last year[4] - Cash inflows from operating activities totaled approximately ¥427.20 million, slightly down from ¥433.67 million, a decrease of about 1.1%[21] - Cash outflows from operating activities increased significantly to approximately ¥469.32 million from ¥309.79 million, resulting in a net cash flow from operating activities of approximately -¥42.12 million[22] - Cash inflows from investment activities were approximately ¥1.45 billion, up from ¥922.01 million, marking an increase of about 57.3%[22] - Cash outflows from investment activities rose to approximately ¥2.12 billion from ¥1.15 billion, leading to a net cash flow from investment activities of approximately -¥669.31 million[22] - The ending cash and cash equivalents balance was approximately ¥585.46 million, down from ¥1.84 billion, indicating a decrease of about 68.3%[22] - The company reported a significant increase in payments to employees, totaling approximately ¥121.99 million, compared to ¥94.45 million in the previous period, an increase of about 29.4%[22] - The company’s cash flow from financing activities resulted in a net outflow of approximately -¥1.70 million, compared to -¥52,856.64 in the previous period, indicating a larger outflow[22] Assets and Liabilities - Total assets at the end of the reporting period increased by 0.92% to CNY 8,478,706,583.73 from CNY 8,401,144,768.99 at the end of the previous year[2] - Total liabilities decreased to ¥852,022,450.92 from ¥913,381,994.27, a reduction of 6.7%[17] - Cash and cash equivalents decreased to ¥586,740,774.48 from ¥1,299,851,770.61, a decline of 54.8%[16] - Inventory slightly decreased to ¥983,308,049.53 from ¥995,427,153.22, a reduction of 1.4%[16] - Non-current assets increased to ¥3,431,232,325.36 from ¥3,342,794,636.95, an increase of 2.6%[17] - The total equity attributable to the parent company increased to ¥7,626,264,685.05 from ¥7,487,150,950.41, reflecting a growth of 1.9%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,155[10] - The largest shareholder, China Resources Pharmaceutical Group, holds 30.45% of shares, totaling 153,540,253 shares[10] - Shenzhen Gaotejia Investment Group holds 11.31% of shares, totaling 57,049,640 shares, with 16,450,000 shares pledged[10] - The top ten shareholders collectively hold significant stakes, with the top three accounting for over 45% of total shares[10] - The company has a total of 0 preferred shareholders at the end of the reporting period[10] - The company has not reported any changes in the number of restricted shares during the reporting period[12] Research and Development - Research and development expenses decreased by 44.40% to CNY 10,566,848.19, primarily due to reduced investment in the Pibin project compared to the previous year[9] - Research and development expenses for the current period were ¥10,566,848.19, down 44.5% from ¥19,006,039.85 in the previous period[19] Regulatory Approvals - The company received approval to set up a blood plasma collection station in Daqing, Inner Mongolia, as of January 2025[12] - The company obtained a clinical trial approval for subcutaneous immunoglobulin for primary immunodeficiency disease in April 2025[13] Shareholder Actions - The controlling shareholder plans to increase its stake by at least 1% (5,042,400 shares) within six months starting from November 8, 2024[14] - As of April 8, 2025, the controlling shareholder has cumulatively increased its stake by 1.17% (5,899,700 shares) since November 8, 2024[14] Impact of Acquisitions - The company's gross profit margin was impacted by the acquisition of Green Cross, with operating costs rising by 71.38% to CNY 247,566,329.70[8] - The company reported a significant increase in accounts receivable by 31.94% to CNY 591,733,607.73, attributed to revenue growth and a decline in cash collections[8]

中信证券股份有限公司 关于华润博雅生物制药集团股份有限公司 募集资金投资项目部分用地被收储的核查意见 根据《深圳证券交易所创业板股票上市规则》（以下简称《股票上市规则》 " "） 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下 简称"《上市公司规范运作》"）等相关规定，中信证券股份有限公司（以 下简称"中信证券"或"保荐机构"）作为华润博雅生物制药集团股份有限公司（以 下简称"博雅生物" 或"公司"）的持续督导保荐机构，对公司募集资金投资项目 部分用地被收储进行了核查。具体情况如下： 一、2018 年非公开发行募集资金基本情况 （一）募集资金基本情况 根据公司 2017 年第二次临时股东大会会议决议及中国证券监督管理委员会 《关于核准博雅生物制药集团股份有限公司非公开发行股票的批复》（证监许可 〔2018〕117 号），核准公司非公开发行不超过 3,750 万股股票。2018 年 4 月 4 日博雅生物制药集团股份有限公司完成了本次非公开发行，实际发行 32,247,662 股，每股发行价格 31.01 元。公司于 2018 年 4 月 4 日收到长城证券股份有限公 司汇缴 ...

Core Viewpoint - China Resources Boya Biopharmaceutical is divesting 80% of its subsidiary Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. for 213 million yuan, indicating a strategic shift due to ongoing financial struggles and market pressures [1] Group 1: Financial Performance - In 2024, Boya Biopharmaceutical's revenue from blood products accounted for 87.29%, but overall revenue declined by 34.58% to 1.735 billion yuan, while net profit increased by 67.18% to 397 million yuan, still below 2022 levels [2] - The company’s plasma collection volume reached 630.6 tons in 2024, a mere 10.4% increase, leaving a significant gap of nearly 60% from its "14th Five-Year Plan" target of 1,000 tons [2] Group 2: Industry Dynamics - The blood product market in China is entering an oligopolistic phase, with the top six companies, including Tian Tan Biological and Shanghai Raist, controlling 80% of plasma collection [2] - Recent acquisitions, such as Shanghai Raist's 4.2 billion yuan purchase of Nanyue Biological, intensify competition, highlighting the challenges faced by Boya Biopharmaceutical in scaling its operations [3] Group 3: Strategic Challenges - The blood product industry has high barriers to entry, with a scarcity of licenses since 2001, making resource acquisition critical for growth [3] - Boya Biopharmaceutical's operational cash flow for 2024 is only 430 million yuan, raising concerns about its ability to compete in a market where acquisition costs are rising [3] Group 4: Future Outlook - The divestment of Boya Xinhao is expected to generate short-term liquidity of 213 million yuan and optimize the asset structure, but long-term growth relies on breakthroughs in the blood product sector [4] - The market anticipates that by 2027, the blood product market in China will reach 78 billion yuan, with a compound annual growth rate of 11.6%, presenting both opportunities and risks for Boya Biopharmaceutical [4]

Core Business Focus - Boya Biological (300294.SZ) plans to sell 80% of its subsidiary Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. for approximately 213 million yuan to concentrate on its core blood products business and optimize resource allocation [1][3][5] Financial Performance - In 2024, Boya Biological reported a revenue of 1.735 billion yuan, a decline of over 34% year-on-year, while the net profit attributable to shareholders increased by nearly 70% to 397 million yuan, although it did not reach the levels of 2022 [2][10] - Boya Xinhao has been operating at a loss, with a reported loss of 34.62 million yuan in 2024 [2][5] Subsidiary Sale Details - The sale of Boya Xinhao, which has a registered capital of approximately 537 million yuan, is expected to result in a loss of about 220 million yuan for Boya Biological, given the recent capital injection of 487 million yuan into the subsidiary [1][8] - The initial valuation for the 80% stake is based on an assessment that values Boya Xinhao at approximately 266 million yuan, indicating a 24.33% increase in value [6] Historical Context - Boya Biological's revenue and net profit have stagnated since its change of ownership in 2021, with significant fluctuations in financial performance observed from 2019 to 2024 [9][10] - The company has reduced its R&D investment from 126 million yuan in 2020 to approximately 97 million yuan in 2024, indicating a potential shift in strategic focus [10] Strategic Moves - In addition to the sale of Boya Xinhao, Boya Biological announced plans to acquire 100% of Green Cross (Hong Kong) Holdings Limited for 1.82 billion yuan to enhance its blood product capabilities [10]

Policy Developments - The National Healthcare Security Administration has established data working groups across all regions, with the aim of enhancing data governance and transparency in healthcare funding [2] Drug and Device Approvals - Jiangsu Tianshili submitted a listing application for the new drug PXT3003, intended for the treatment of Charcot-Marie-Tooth disease type 1A [4] Capital Markets - Ruijian Pharmaceutical completed nearly 100 million RMB in B+ round financing, bringing total financing to over 200 million RMB in less than six months [6] - Weichan Medical announced the completion of several million RMB in angel round financing, aimed at accelerating product development and market entry [7] - Novartis plans to invest $23 billion in the U.S. over the next five years to enhance production capabilities and ensure the domestic supply of critical medications [8] Industry Events - Boya Bio disclosed plans to sell 80% of its subsidiary, Boya Xinha, to focus on its core blood products business, with an initial listing price of 213 million RMB [10] Financial Reports - Pumen Technology reported a revenue of 1.148 billion RMB for 2024, with a net profit of 345 million RMB, reflecting a 5.12% increase [12] - Huaxi Biotechnology's revenue for 2024 was 5.371 billion RMB, down 11.61%, with a net profit of 174 million RMB, down 70.59% [13] - Watson Bio reported a revenue of 2.821 billion RMB for 2024, down 31.41%, with a net profit of 142 million RMB, down 66.10% [14] - Innovation Medical reported a revenue of 816 million RMB for 2024, with a net loss of 93.95 million RMB [15] - People's Tongtai reported a revenue of 10.048 billion RMB for 2024, down 3.29%, with a net profit of 213 million RMB, down 27% [16] - Haizike reported a revenue of 3.721 billion RMB for 2024, with a net profit of 395 million RMB, up 34% [17] - Hainan Haiyao reported a revenue of approximately 999 million RMB for 2024, down 33%, with a net loss of 1.525 billion RMB [18] - Wantai Bio reported a revenue of approximately 2.245 billion RMB for 2024, down 59.25%, with a net profit of 106 million RMB, down 91.49% [19] Public Opinion Alerts - Xinghao Pharmaceutical announced the resignation of director Li Huiqu due to personal reasons, effective April 11, 2025 [21] - Zhaoyan New Drug acknowledged unusual fluctuations in its stock price, linked to a recent FDA plan that may impact the industry [23]

这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 各地医保数据工作组基本完成首次信息发布工作 国家医保局4月11日消息，目前，全国所有统筹地区均已建立医保数据工作组，主要由医保部门、定点 医疗机构代表组成，日常承担数据分析、政策答疑等工作，并按月或季度发布数据信息。截至3月31 日，除广西的个别统筹地区外，全国其他统筹地区均已完成2025年第一季度发布。下一步，国家医保局 将指导地方健全完善数据工作组机制，常态化做好数据发布，不断提高数据发布质量。 21点评：医保部门充分发挥数据治理效能，通过机构间、病种间数据比较，为医疗机构服务质效精 准"画像"。通过数据定向发布工作的开展，各地医保部门积极向定点医药机构亮医保基金家底、晒医保 改革进展、比两定机构服务绩效和服务水平、守基金安全底线、稳医疗机构预期，提升医保基金透明 度，进一步提升了医保精细化管理水平。 药械审批 天士力腓骨肌萎缩症1A型药物上市申请递交 4月11日，国家药品监督管理局药品审评中心官网显示，江苏天士力（600535）帝益药业有限公司递交 了2.3类新药PXT3003的上市申请，PXT300 ...

4月13日晚间博雅生物（300294）披露，为聚焦血液制品主业，优化公司资源配置，提升公司资本回报 水平，公司拟通过上海联合产权交易所挂牌转让江西博雅欣和制药有限公司(下称"博雅欣和")80%股 权。 公告显示，交易拟采取公开挂牌方式进行，首次挂牌金额为2.13亿元(以经国有资产监督管理机构授权 单位备案的评估价值为准)，尚未确定交易对象，目前无法判断是否涉及关联交易。 据披露，博雅欣和于2014年成立，主营业务为抗感染类、糖尿病类、心脑血管类药品的研发、生产和销 售。公司位于抚州高新技术产业园区东二区，在建厂时主要围绕西他沙星片的生产而建设配套产线，主 体工程由非无菌化学原料药生产和口服固体制剂生产两大生产系统构成。因前期西他沙星片销售一直未 获批或中标，期间博雅欣和公司寻求其他适配产线的产品或承接代工业务以维持经营，业务量和业务收 入呈现不稳定现象。2023年11月，根据《关于公布全国药品集中采购(GY-YD2023-2)中选结果的通 知》，西他沙星片中选国家第九批药品集中采购。 2024年，博雅生物全年实现采浆630.6吨，同比增长10.4%。其中华润博雅生物本部采浆522.04吨，同比 增长11.7% ...

博雅生物（300294）公告，公司拟通过上海联合产权交易所公开挂牌转让江西博雅欣和制药有限公司 80%股权。首次挂牌金额为2.13亿元，交易对象、交易价格和交易时间尚未确定，交易成功与否存在不 确定性。此次股权转让旨在优化公司资源配置，聚焦血液制品主业，提升资本回报水平。转让完成后， 博雅欣和将不再纳入公司合并报表范围。公司将根据交易进展情况及时履行信息披露义务。此次交易不 构成重大资产重组。 ...

本报告依据中国资产评估准则编制 华润博雅生物制药集团股份有限公司 拟转让江西博雅欣和制药有限公司 股权项目 资产评估报告 中企华评报字(2024)第 6691 号 (共一册，第一册) 北京中企华资产评估有限责任公司 二○二五年三月三十一日 | 声 明 1 | | | --- | --- | | 资产评估报告摘要 3 | | | 资产评估报告正文 5 | | | 一、委托人、被评估单位和资产评估委托合同约定的其他资产评估报告使用人 | 5 | | 二、评估目的 | 10 | | 三、评估对象和评估范围 | 10 | | 四、价值类型 | 15 | | 五、评估基准日 | 15 | | 六、评估依据 | 15 | | 七、评估方法 | 20 | | 八、评估程序实施过程和情况 | 34 | | 九、评估假设 | 37 | | 十、评估结论 | 38 | | 十一、特别事项说明 | 40 | | 十二、资产评估报告使用限制说明 | 42 | | 十三、资产评估报告日 | 43 | | 资产评估报告附件 44 | | 华润博雅生物制药集团股份有限公司拟转让江西博雅欣和制药有限公司股权项目资产评估报告 声 明 一、本资 ...